17th Congress of the EHA 2012 on June 14th (clocate.com

17th Congress of the EHA 2012
June 14 - 17, 2012
Helsinki Exhibition and Convention Centre (Helsingin Messukeskus)
Helsinki, Finland
The Annual Congress of the European Hematology Association invites you to come and experience the next step
of this annual European event.

As in previous years the Scientific Program Committee (SPC), its
Advisory Board and all other committees involved have done their utmost
to create a program that promotes excellence in all fields of
hematology. Its Plenary Sessions are designed to be of interest to all
specialties with key note speakers providing interesting presentations.
The highly valued Education Sessions and Hematology-in-Focus offer a
wide range of topics discussed on many levels. Joint symposia will be
organized with the American Society of Hematology, the European School
of Haematology and a new collaboration with the Japanese Society of
Hematology has resulted in a special symposium.

            
Another highlight in the organization of the Congress is the
well-established Molecular Hemopoiesis Workshop, preceded in the
morning with the brand new Laboratory Hematology Workshop. This new
workshop will bring an extended focus on diagnostics into the program.
Furthermore, the lunch debates are in heated preparation at the moment,
already causing a rumor within the SPC. The Meet-the-Experts will offer
a chance to discuss and put your questions before an authority in
hematology and the Scientific Working Groups are designing their
sessions to show also their valued scientific work.
Venue
Helsinki Exhibition and
Convention Centre (Helsingin
Messukeskus)
Address
Messuaukio 1,

Helsinki,

Finland
Exhibition
Yes
Website

							  www.ehaweb.org/Congress/Future-Congresses
Categories
					
					
Health: Hematology

Update
event

Contact
Organizer

Reminder
Updates

Post
a Review

Recommend
a Restaurant

Recommend
an Attraction

Post
an Article

Important

Please, check the conference website for possible changes, before you make any traveling arrangements

* Prices are for evaluation only.

Articles/News/Press releases

Chronic lymphocytic leukemia and related disorders - Clinical

EFFICACY OF SPLENECTOMY IN HAIRY-CELL LEUKEMIA (HCL)

Yevstakhevych Y. L., Vyhovska Y. I., Yevstakhevych I. Y.,

Indenko V. F., Vyhovska O. Y., Loginsky V. Y.

State Institution “Research Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine”

Background. Since 1980s, introduction of interferon-α (IFNα)-based medications has launched a new era in the treatment of HCL. Clinical application of analogues of purine nucleosides, 2-chlordesoxyadenosine (2CdA, Cladribine) and 2-desoxycoformicine (DCF, Pentostatin) proved even more effective: a remission was stated in 80-100% patients, including those refractory to previous therapy. However, neither interferon nor purine analogues do not allow to secure a complete recovery in HCL, as shown by various investigators. Noteworthy, some patients develop severe adverse events following application of these drugs. Therefore, splenectomy is becoming an important treatment option in patients with HCL.

Aims. The study was designed to retrospectively analyze the efficacy of splenectomy in 27 patients with HCL and determine the importance of this operation in up-to-date treatment of HCL.

Methods. 27 patients with HCL, who underwent splenectomy during 1984-2004, have been observed. There were 17 males aged between 30-60 y. and 10 females aged between 32-54 y. The median age of patients was 45 years.

Results. An analysis of long-term outcomes of splenectomy in 27 patients with HCL has been undertaken. Among 25 patients who underwent splenectomy as a first-line therapy, both 5-year and 10-year uneventful survivals were achieved in 45%, while a 20-year survival was stated in 35%. Cladribine (2CdA) proved the most effective treatment for postoperative relapses of HCL. Two patients were initiated on splenectomy as a second-line therapy after previous management with 2CdA and IFNα turned to be ineffective.

Conclusions. Splenectomy in patients with HCL performed for splenomegaly, marked cytopenias, and inefficacy of previous treatment helps achieve a complete clinical and hematological remission (reversal of cytopenia, disappearance of hairy cells in peripheral blood) in 80.8% patients, while the rest of them show a partial remission. Splenectomy performed as first-line therapy in patients with HCL makes it possible to attain a lasting remission (18-25 years) in 30.4% of the cases, whereas relapses of leukemia have been stated in 52.2%. Relapses of HCL after splenectomy are successfully treated with 2CdA and/or IFNα-based medications.

Кey words: hairy-cell leukemia, splenectomy, survival, 2-chlordesoxyadenosine, interferon-α
A Study of clinical profile and treatment outcome of DOTS regime in 250 pulmonary and extra pulmonary patients in Hamidia hospital ,Bhopal in the year 2011
Mechanisms of hearing loss in prematures and fullterms with perinatal or postnatal hypoxia
Cochlear Implantation in Auditory Neuropathy
Infection Control
Health conferences